16 October 2012 ETT Medtech Summit 2012 ETT Medtech Summit 2012 16th-17th October 2012, Lausanne, Switzerland The European Tech Tour Association will present its third Medtech Summit on October 16-17th 2012 with 100+ delegates and 25 presenting ceos. Europe is uniquely positioned in the medtech environment as THE place for clinical and technical innovation. Europe's aging population provides ample market opportunities for start ups to bring effective and cost efficient solutions to treat patients. This edition's theme will be 'Bridge to Asia'. Asia offers European Medtech start ups a major opportunity for accelerated development, with an average growth of 10% and market value expected to exceed 50billion euros by 2015. Asia provides growth and critical mass with Japan as the second largest market and China to become the third largest world market in the coming decade. Beyond efficient operational models and access to high growth markets, Asia is now well positioned to offer critical capabilities in terms of quality product development, clinical trials, financing and exit opportunities. This edition of the Medtech Summit will gather relevant medtech actors in the Asia to provide an opportunity to nurture this topic. Jean Luc Butel, president of International for Baxter, will be the key note speaker. A panel of Asian venture capitalists and entrepreneurs is on the agenda. BioBay, Suzhou based Life Sciences corporation is partnering with the Medtech Summit for this event. Click here for more information. Contributor European Tech Tour Association Comment on this article Websites http://www.cvent.com/events/ett-medtech-summit-2012/event-summary-5654f0b2df06415695cbce13eb7dd1f8.aspx?i=8309bff4-d9ff-4c26-a052-b35b39e44783 This material is protected by MA Business copyright See Terms and Conditions. One-off usage is permitted but bulk copying is not. For multiple copies contact the sales team. What you think about this article: Add your comments Name Email Comments Your comments/feedback may be edited prior to publishing. Not all entries will be published. Please view our Terms and Conditions before leaving a comment.